Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus

Chinese Medical Journal

Volumn 121, Issue 21, 2008, Pages 2124-2128

  Zhang, Wei ^a   Xu, Yan Cheng ^a   Guo, Fang Jian ^a   Meng, Ye ^a   Li, Ming Li ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Berberine; Cinnamaldehyde; Glucose transporter 4; Insulin resistance; Retinol binding protein 4; Type 2 diabetes mellitus

Indexed keywords

BERBERINE; CINNAMALDEHYDE; GLUCOSE; GLUCOSE TRANSPORTER 4; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RETINOL BINDING PROTEIN 4; STREPTOZOCIN; ACROLEIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, RAT; SLC2A4 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; EXPERIMENTAL MODEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HYPOGLYCEMIA; HYPOLIPEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; BODY WEIGHT; METABOLISM; WISTAR RAT;

ACROLEIN; ANIMALS; BERBERINE; BLOTTING, WESTERN; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GLUCOSE TRANSPORTER TYPE 4; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; RATS; RATS, WISTAR; RETINOL-BINDING PROTEINS, PLASMA;

EID: 58149360797     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200811010-00003     Document Type: Article

References (34)

1. Kahn BB. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell 1998; 92: 593-596.
2. Muoio DM, Newgard CB. Molecular and metabolic mechanisms of insulin resistance and cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 193-205.
3. Guerre-Millo M. Adiponectin: an update. Diabetes Metab 2008; 34: 12-18.
4. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, et al. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008; 57: 980-986.
5. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
6. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
7. Yang Q, Graham TE, Mody N, Preitner F, Peroniet OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362.
8. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TC, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563.
9. Craig RL, Chu WS, Elbein SC. Retinol binding protein 4 as a candidate gene for type 2 diabetes and prediabetic intermediate traits. Mol Genet Metab 2007; 90: 338-344.
10. Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008; 8: 99-111.
11. Babu PS, Prabuseenivasan S, Ignacimuthu S. Cinnamaldehyde - a potential antidiabetic agent. Phytomedicine 2007; 14: 15-22.
12. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53 Suppl 1: s119-s124.
13. McGarry JD. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
14. Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord 2008 Sep 6.
15. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008; 29: 351-366.
16. Waki H, Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol Mech Dis 2007; 2: 31-56.
17. Ahima RS, Osei SY. Adipokines in obesity. Front Horm Res 2008; 36: 182-197.
18. Laza MA. How obesity causes diabetes: not a tall tale. Science 2005; 307: 373-375.
19. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008 Sep 5.
20. Noy N. Retinoid-binding proteins: mediators of retinoid action. Biochem J 2000; 348 (Pt 3): 481-495.
21. Polonsky KS. Retinol-binding protein 4, insulin resistance, and type 2 diabetes. N Engl J Med 2006; 354: 2596-2598.
22. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 2457-2461.
23. Jia W, Wu H, Bao Y, Wang C, Lu J, Zhu J, et al. Association of serum retinol binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab (Chin) 2007; 8: 3224-3229.
24. Sasaki R, Nishimura N, Hoshino H, Isa Y, Kadowaki M, Ichi T, et al. Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice. Biochem Pharmacol 2007; 74: 1619-1627.
25. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab (Chin) 2008; 93: 2559-2565.
26. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10: 1344-1351.
27. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005; 25: 2170-2176.
28. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006; 55: 2256-2264.
29. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008; 57: 1414-1418.
30. Liu WH, Li XJ, Nie H, Tang FT, Huang HQ, Hei ZQ, et al. Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J 2008; 121: 706-712.
31. Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 2003; 26: 3215-3218.
32. Qin B, Nagasaki M, Ren M, Bajotto G, Oshida Y, Sato Y. Cinnamon extract prevents the insulin resistance induced by a high-fructose diet. Horm Metab Res 2004; 36: 119-125.
33. Blevins SM, Leyva MJ, Brown J, Wright J, Scofield RH, Aston CE. Effect of cinnamon on glucose and lipid levels in non-insulin-dependent type 2 diabetes. Diabetes Care 2007; 30: 2236-2237.
34. Kawaguchi R, Yu JM, Honda J, Hu J, Whitelegge J, Ping PP, et al. A member receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 2007; 315: 820-825.